RESUMEN
Current methods for vector-borne disease surveillance are limited by time and cost. To avoid human infections from emerging zoonotic diseases, it is important that the United States develop cost-effective surveillance systems for these diseases. This study examines the methodology used in the surveillance of a plague epizootic involving tree squirrels (Sciurus niger) in Denver Colorado, during the summer of 2007. A call-in centre for the public to report dead squirrels was used to direct animal carcass sampling. Staff used these reports to collect squirrel carcasses for the analysis of Yersinia pestis infection. This sampling protocol was analysed at the census tract level using Poisson regression to determine the relationship between higher call volumes in a census tract and the risk of a carcass in that tract testing positive for plague. Over-sampling owing to call volume-directed collection was accounted for by including the number of animals collected as the denominator in the model. The risk of finding an additional plague-positive animal increased as the call volume per census tract increased. The risk in the census tracts with >3 calls a month was significantly higher than that with three or less calls in a month. For tracts with 4-5 calls, the relative risk (RR) of an additional plague-positive carcass was 10.08 (95% CI 5.46-18.61); for tracts with 6-8 calls, the RR = 5.20 (2.93-9.20); for tracts with 9-11 calls, the RR = 12.80 (5.85-28.03) and tracts with >11 calls had RR = 35.41 (18.60-67.40). Overall, the call-in centre directed sampling increased the probability of locating plague-infected carcasses in the known Denver epizootic. Further studies are needed to determine the effectiveness of this methodology at monitoring large-scale zoonotic disease occurrence in the absence of a recognized epizootic.
Asunto(s)
Líneas Directas , Peste/epidemiología , Enfermedades de los Roedores/epidemiología , Sciuridae , Yersinia pestis/aislamiento & purificación , Animales , Anticuerpos Antibacterianos , Colorado/epidemiología , Epidemias/veterinaria , Monitoreo Epidemiológico , Humanos , Insectos Vectores/microbiología , Peste/microbiología , Reacción en Cadena de la Polimerasa , Factores de Riesgo , Enfermedades de los Roedores/microbiología , Siphonaptera/microbiología , Población Urbana , Yersinia pestis/genética , Yersinia pestis/inmunología , ZoonosisRESUMEN
BACKGROUND AND PURPOSE: As a combination of 5-HT selective reuptake inhibitor (SSRI) with 5-HT(1A) receptor antagonism may yield a rapidly acting antidepressant, WAY-211612, a compound with both SSRI and 5-HT(1A) receptor antagonist activities, was evaluated in preclinical models. EXPERIMENTAL APPROACH: Occupancy studies confirmed the mechanism of action of WAY-211612, while its in vivo profile was characterized in microdialysis and behavioural models. KEY RESULTS: WAY-211612 inhibited 5-HT reuptake (K(i) = 1.5 nmol.L(-1); K(B) = 17.7 nmol.L(-1)) and exhibited full 5-HT(1A) receptor antagonist activity (K(i) = 1.2 nmol.L(-1); K(B) = 6.3 nmol.L(-1); I(max) 100% in adenyl cyclase assays; K(B) = 19.8 nmol.L(-1); I(max) 100% in GTPgammaS). WAY-211612 (3 and 30 mg.kg(-1), po) occupied 5-HT reuptake sites in rat prefrontal cortex (56.6% and 73.6% respectively) and hippocampus (52.2% and 78.5%), and 5-HT(1A) receptors in the prefrontal cortex (6.7% and 44.7%), hippocampus (8.3% and 48.6%) and dorsal raphe (15% and 83%). Acute or chronic treatment with WAY-211612 (3-30 mg.kg(-1), po) raised levels of cortical 5-HT approximately twofold, as also observed with a combination of an SSRI (fluoxetine; 30 mg.kg(-1), s.c.) and a 5-HT(1A) antagonist (WAY-100635; 0.3 mg.kg(-1), s.c). WAY-211612 (3.3-30 mg.kg(-1), s.c.) decreased aggressive behaviour in the resident-intruder model, while increasing the number of punished crossings (3-30 mg.kg(-1), i.p. and 10-56 mg.kg(-1), po) in the mouse four-plate model and decreased adjunctive drinking behaviour (56 mg.kg(-1), i.p.) in the rat scheduled-induced polydipsia model. CONCLUSIONS AND IMPLICATIONS: These findings suggest that WAY-211612 may represent a novel antidepressant.
Asunto(s)
Antidepresivos de Segunda Generación/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Antagonistas del Receptor de Serotonina 5-HT1 , Antagonistas de la Serotonina/farmacología , Animales , Conducta Animal/efectos de los fármacos , Cromatografía Líquida de Alta Presión , AMP Cíclico/metabolismo , Masculino , Ratones , Microdiálisis , Ratas , Ratas Sprague-DawleyRESUMEN
Demonstration of neurogenesis in adult brain represents a major advance in our understanding of the cellular mechanisms underlying neuronal remodeling and complex behavior. Recent studies from our laboratory and others demonstrate that chronic administration of an antidepressant, including either a 5-HT or norepinephrine selective reuptake inhibitor, up-regulates neurogenesis in adult rodent hippocampus. Up-regulation of neurogenesis could block or reverse the effects of stress on hippocampal neurons, which include down-regulation of neurogenesis, as well as atrophy. The possibility that the cAMP signal transduction cascade contributes to the regulation of neurogenesis by antidepressants is supported by previous studies and by recent work. Although additional studies must be conducted to determine the significance of adult neurogenesis in humans, these findings will stimulate new avenues of research to identify the cellular and molecular basis of stress-related mood disorders as well as the development of novel therapeutic strategies.
Asunto(s)
Antidepresivos/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/crecimiento & desarrollo , Neuronas/fisiología , Humanos , Trastornos del Humor/patología , Neuronas/efectos de los fármacosRESUMEN
Proliferation and maturation of neurons has been demonstrated to occur at a significant rate in discrete regions of adult brain, including the hippocampus and subventricular zone. Moreover, adult neurogenesis is an extremely dynamic process that is regulated in both a positive and negative manner by neuronal activity and environmental factors. It has been suggested to play a role in several important neuronal functions, including learning, memory, and response to novelty. In addition, exposure to psychotropic drugs or stress regulates the rate of neurogenesis in adult brain, suggesting a possible role for neurogenesis in the pathophysiology and treatment of neurobiological illnesses such as depression, post-traumatic stress disorder, and drug abuse. As the mechanisms that control adult neurogenesis continue to be identified, the exciting prospect of developing pharmacological agents that specifically regulate the proliferation and maturation of neurons in the adult brain could be fulfilled.
Asunto(s)
Neuronas/efectos de los fármacos , Neuronas/patología , Psicotrópicos/farmacología , Estrés Fisiológico/patología , Adulto , Animales , División Celular/efectos de los fármacos , División Celular/fisiología , Humanos , Mitosis/efectos de los fármacos , Mitosis/fisiologíaRESUMEN
Studies at the basic and clinical levels demonstrate that neuronal atrophy and cell death occur in response to stress and in the brains of depressed patients. Although the mechanisms have yet to be fully elucidated, progress has been made in characterizing the signal transduction cascades that control neuronal atrophy and programmed cell death and that may be involved in the action of antidepressant treatment. These pathways include the cyclic adenosine monophosphate and neurotrophic factor signal transduction cascades. It is notable that these same pathways have been demonstrated to play a pivotal role in cellular models of neural plasticity. This overlap of plasticity and cell survival pathways, together with studies demonstrating that neuronal activity enhances cell survival, suggests that neuronal atrophy and death could result from a disruption of the mechanisms underlying neural plasticity. The role of these pathways and failure of neuronal plasticity in stress-related mood disorders are discussed.
Asunto(s)
Trastornos del Humor , Plasticidad Neuronal/fisiología , Neuronas/patología , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Atrofia/etiología , Atrofia/genética , Atrofia/patología , Factor Neurotrófico Derivado del Encéfalo/efectos de los fármacos , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Muerte Celular/efectos de los fármacos , Muerte Celular/genética , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/genética , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/efectos de los fármacos , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Genes bcl-2/efectos de los fármacos , Genes bcl-2/genética , Humanos , Trastornos del Humor/tratamiento farmacológico , Trastornos del Humor/etiología , Trastornos del Humor/metabolismo , Plasticidad Neuronal/genética , Neuronas/metabolismo , Células Piramidales/efectos de los fármacos , Células Piramidales/metabolismo , Receptores de AMP Cíclico/efectos de los fármacos , Receptores de AMP Cíclico/metabolismo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Estrés Psicológico/psicología , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiologíaRESUMEN
Recent studies suggest that stress-induced atrophy and loss of hippocampal neurons may contribute to the pathophysiology of depression. The aim of this study was to investigate the effect of antidepressants on hippocampal neurogenesis in the adult rat, using the thymidine analog bromodeoxyuridine (BrdU) as a marker for dividing cells. Our studies demonstrate that chronic antidepressant treatment significantly increases the number of BrdU-labeled cells in the dentate gyrus and hilus of the hippocampus. Administration of several different classes of antidepressant, but not non-antidepressant, agents was found to increase BrdU-labeled cell number, indicating that this is a common and selective action of antidepressants. In addition, upregulation of the number of BrdU-labeled cells is observed after chronic, but not acute, treatment, consistent with the time course for the therapeutic action of antidepressants. Additional studies demonstrated that antidepressant treatment increases the proliferation of hippocampal cells and that these new cells mature and become neurons, as determined by triple labeling for BrdU and neuronal- or glial-specific markers. These findings raise the possibility that increased cell proliferation and increased neuronal number may be a mechanism by which antidepressant treatment overcomes the stress-induced atrophy and loss of hippocampal neurons and may contribute to the therapeutic actions of antidepressant treatment.
Asunto(s)
Antidepresivos/farmacología , Hipocampo/efectos de los fármacos , Neuronas/efectos de los fármacos , Animales , Antígenos de Diferenciación/metabolismo , Bromodesoxiuridina , Recuento de Células , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Técnica del Anticuerpo Fluorescente , Fluoxetina/farmacología , Hipocampo/citología , Hipocampo/metabolismo , Masculino , Morfolinas/farmacología , Neuronas/citología , Neuronas/metabolismo , Ratas , Ratas Sprague-Dawley , Reboxetina , Tranilcipromina/farmacologíaRESUMEN
Adaptations at the cellular and molecular levels in response to stress and antidepressant treatment could represent a form of neural plasticity that contributes to the pathophysiology and treatment of depression. At the cellular level, atrophy and death of stress-vulnerable neurons in the hippocampus, as well as decreased neurogenesis of hippocampal neurons, has been reported in preclinical studies. Clinical studies also provide evidence for atrophy and cell death in the hippocampus, as well as the prefrontal cortex. It is possible that antidepressant treatment could oppose these adverse cellular effects, which may be regarded as a loss of neural plasticity, by blocking or reversing the atrophy of hippocampal neurons and by increasing cell survival and function. The molecular mechanisms underlying these effects are discussed, including the role of the cAMP signal transduction cascade and neurotrophic factors.
Asunto(s)
Antidepresivos/farmacología , Depresión/fisiopatología , Plasticidad Neuronal/efectos de los fármacos , Estrés Psicológico/fisiopatología , Antidepresivos/uso terapéutico , Muerte Celular , Hormona Liberadora de Corticotropina/metabolismo , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Depresión/tratamiento farmacológico , Depresión/metabolismo , Hipocampo/metabolismo , Hipocampo/patología , Humanos , Norepinefrina/metabolismo , Corteza Prefrontal/metabolismo , Corteza Prefrontal/patología , Transducción de Señal/efectos de los fármacos , Estrés Psicológico/metabolismoRESUMEN
The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA) is a drug of abuse and has been shown to be neurotoxic to 5-HT terminals in many species. MDMA-engendered neurotoxicity has been shown to be affected by both ambient temperature and core body temperature. We now report that small (2 degreesC) changes in ambient temperature produce changes in core temperature in MDMA-treated rats, but the same changes in ambient temperature do not affect core temperature of saline-treated animals. Furthermore, increases in core temperature of MDMA-treated animals increase neurotoxicity. Rats were given MDMA (20 or 40 mg/kg) or saline and placed in an ambient temperature of 20, 22, 24, 26, 28, or 30 degreesC using a novel temperature measurement apparatus that controls ambient temperature +/-0.5 degrees C. Two weeks after MDMA treatment, the rats were killed, and regional 5-HT and 5-hydroxyindole acetic acid levels were analyzed as a measure of neurotoxicity. Rats treated with MDMA at 20 and 22 degrees C showed a hypothermic core temperature response. Treatment with MDMA at 28 and 30 degreesC produced a hyperthermic response. At ambient temperatures of 20-24 degrees C, neurotoxicity was not observed in the frontal cortex, somatosensory cortex, hippocampus, or striatum. At ambient temperatures of 26-30 degrees C, neurotoxicity was seen and correlated with core temperature in all regions examined. These data indicate that ambient temperature has a significant affect on MDMA neurotoxicity, core temperature, and thermoregulation in rats. This finding has implications on both the temperature dependence of the mechanism of MDMA neurotoxicity and human use because fatal hyperthermia is associated with MDMA use in humans.
Asunto(s)
Temperatura Corporal/efectos de los fármacos , N-Metil-3,4-metilenodioxianfetamina/toxicidad , Serotoninérgicos/toxicidad , Temperatura , Ácido 3,4-Dihidroxifenilacético/análisis , Animales , Regulación de la Temperatura Corporal/efectos de los fármacos , Química Encefálica/efectos de los fármacos , Cuerpo Estriado/química , Dopamina/análisis , Fiebre/metabolismo , Fiebre/mortalidad , Lóbulo Frontal/química , Hipocampo/química , Ácido Homovanílico/análisis , Ácido Hidroxiindolacético/análisis , Ácido Hidroxiindolacético/metabolismo , Masculino , Neurotoxinas/farmacología , Ratas , Ratas Sprague-Dawley , Serotonina/análisis , Serotonina/metabolismo , Cloruro de Sodio/farmacología , Corteza Somatosensorial/químicaRESUMEN
This study investigated the effect of two different ambient temperatures on fenfluramine-induced 5-HT neurotoxicity. Fenfluramine (FEN) (12.5 mg/kg x 4; injections made hourly) or saline (SAL) was administered to rats in either a normal laboratory temperature of 24 degrees C or a warm environment of 30 degrees C. Animals were kept at that ambient temperature for 20 h after FEN administration. Ambient temperature was controlled to +/-0.5 degrees C and rat core temperature was continually measured using a non-invasive apparatus. FEN-treated rats at 24 degrees C displayed a core temperature hypothermia with a peak low of 33.8 degrees C, and this core temperature hypothermia lasted for 20 h after FEN administration. Rats treated with FEN at 30 degrees C displayed a significant core temperature hyperthermia for 4 h after the first drug injection compared to SAL-treated groups, with a peak core temperature of 38.6 degrees C. 2 weeks after FEN injections, brain regions were analyzed by HPLC. Both groups of FEN-treated rats showed decreases in 5-HT and 5-HIAA in the hippocampus, frontal cortex, somatosensory cortex, striatum, hypothalamus and septum. However, FEN rats treated at 30 degrees C had significantly greater decreases (26-35%) in 5-HT compared to FEN-treated rats at 24 degrees C in the frontal cortex, hippocampus, striatum and somatosensory cortex and significantly greater decreases (26-50%) in 5-HIAA in the frontal cortex, hippocampus and somatosensory cortex. This study indicates fenfluramine can produce neurotoxicity in rats that display either a core temperature hypothermia or hyperthermia, although hyperthermic rats have greater 5-HT and 5-HIAA depletions than the hypothermic rats.
Asunto(s)
Regulación de la Temperatura Corporal/efectos de los fármacos , Fenfluramina/farmacología , Neuronas/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Serotonina/toxicidad , Animales , Encéfalo/citología , Encéfalo/efectos de los fármacos , Química Encefálica/efectos de los fármacos , Química Encefálica/fisiología , Muerte Celular/efectos de los fármacos , Fiebre/inducido químicamente , Fiebre/fisiopatología , Ácido Hidroxiindolacético/metabolismo , Ratas , Ratas Sprague-Dawley , Serotonina/metabolismo , Serotonina/fisiología , Temperatura , Factores de TiempoRESUMEN
The substituted amphetamine 3,4-methylenedioxymethamphetamine (MDMA) has been shown to be neurotoxic to serotonin (5HT) terminals in the rat, and rat body temperature (TEMP) has been shown to affect this neurotoxicity. This study looked at the effect on CORE TEMP of three drugs that protect against MDMA neurotoxicity in the rat. Male Holtzmann rats were injected with a control saline (SAL) injection or with ketanserin (KET; 6 mg/kg), alpha-methyl-p-tyrosine (AMPT; 75 mg/kg) or fluoxetine (FLUOX; 10 mg/kg) before a 40-mg/kg MDMA or SAL injection. CORE TEMP was recorded throughout the study using a noninvasive peritoneally implanted temperature probe. Rats pretreated with KET had no change in CORE TEMP until MDMA was injected, at which time an immediate hypothermia was seen that continued for 180 minutes, with a peak low of 34.7 degrees C. Rats treated with AMPT had no change in CORE TEMP until the MDMA was injected, at which time an immediate hypothermia was seen that continued for 240 min., with a peak low of 34.3 degrees C. Two weeks later, brain regions were analyzed for 5-HT and 5-hydroxindole acetic acid levels. MDMA produced significant (P < .05) decreases in 5-HT and 5-hydroxindole acetic acid levels in the frontal cortex, somatosensory cortex, striatum and hippocampus, and pretreatment with KET or AMPT prevented these depletions. When rats were given the KET/MDMA or AMPT/MDMA drug injections and warmed to prevent hypothermia, the protection against neurotoxicity was removed, which indicated that the hypothermia mediated the protective effects of KET and AMPT. In comparison with the hypothermia seen with AMPT or KET pretreatment, pretreatment with FLUOX had no effect on CORE TEMP. The rats given the FLUOX/MDMA treatment did not have different CORE TEMPs than rats given SAL/MDMA. The FLUOX pretreatment protected against MDMA-induced 5-HT and 5-hydroxindole acetic acid depletions in the frontal cortex, somatosensory cortex, striatum and hippocampus. This study suggests that a decrease in CORE TEMP may be a mechanism of protection against MDMA neurotoxicity by some drugs but that there is also a mechanism of protection that is independent of a change in body temperature.